Seeking Alpha

In contrast to Clovis' share-price collapse, Celgene (CELG) is +8.6% after saying on Friday that...

In contrast to Clovis' share-price collapse, Celgene (CELG) is +8.6% after saying on Friday that its Abraxane treatment for advanced pancreatic cancer lengthened the survival of patients in a Phase III study. Pancreatic cancer could add up to $1B in sales of Abraxane, which is already approved to treat breast and lung tumors.
Comments (1)
  • Great news for patients of this terrible disease. There were many anekdotal rumors on cancer web sites on the efficiency of Abraxene in pancreatic cancer. The mechanism involves targeted delivery and thus the compatibility of the drug is much better than of the taxol.
    12 Nov 2012, 08:54 AM Reply Like
DJIA (DIA) S&P 500 (SPY)